After Zhong Suansui, can the 9-valent HPV vaccine recreate the richest man in China?

Zhong Sui Sui of Wantai Biotechnology put "water" into the vaccine bottle and became the richest man in China in 2021
.

In the above information, no matter whether it is a person or a company, it is undoubtedly conveying a message to us: "The vaccine is good, and the new crown vaccine is better
.

So who will be the next "vaccine star" to take over the new crown vaccine? Perhaps the 9-valent HPV vaccine with epoch-making significance can even become the "top stream"
.

In fact, no matter it is 2, 4 or 9 prices, it is difficult to find a single shot in China and even in the world.
If the situation of housing and car lottery is still only in Shanghai, Beijing and other super first-tier cities, then HPV vaccine The 9-valent vaccination lottery situation in China is a widespread phenomenon across the country
.

Many young ladies are also very concerned about the domestic replacement of the 9-valent HPV vaccine.
Their eagerly anticipated mood is widely spread in major domestic forums.
Some even ridiculed "My mother can wait, but the age of my mother can't wait.
Domestic vaccines No longer on the market, I have to prepare for my daughter in advance
.

Indeed, according to relevant data, the most important reason why the 9-price HPV vaccine is more popular than other types of HPV vaccine is that it can cover more than 90% of the virus that causes cervical cancer, which greatly reduces the cancer risk of women of the right age.
The only drug that can prevent tumors is an epoch-making product at the beginning of its birth.
The 9-valent HPV vaccine is also the variety with the largest market share and the most popular among all HPV vaccines
.

But on the other hand, because there is only one Merck & Co.
company in the world that produces 9-valent HPV vaccines, it needs to meet the needs of hundreds of millions of young ladies all over the world.
It also greatly limits the popularization of human health
.

At present, the fastest domestic 9-valent HPV vaccine research and development progress is in clinical phase III, and there are 4 companies in this phase, namely Bowei Biotechnology, Wantai Biotechnology, Kangleweishi and Ruike Biotechnology, and vaccine companies before Phase III Although there are many, there is a high probability that they will miss the "first prize"
.

Note: At present, Kangleweishi 9-valent HPV vaccine has entered phase III clinical trials, and the first subject was successfully enrolled on December 5, 2020
.

Among the four companies at the forefront of the R&D progress, the only ones that are most likely to compete for the "starter" lineup are Bowei Biotech and Wantai Biotech
.

First of all, as the first to enter the clinical phase III in April this year, Bowei Biotechnology mainly relies on its core genetic engineering recombinant protein VLP vaccine development technology platform.
Unlike traditional monomeric recombinant protein products, there are hundreds of virus-like particles.
The aggregates of monomer molecules range in size from ten nanometers to hundreds of nanometers, and their molecular weight is hundreds or even thousands of times that of ordinary proteins
.

In 2016, the special subsidiary "Chongqing Bowei Baitai" was responsible for the advancement of 9-valent HPV vaccine related work.

Secondly, as the first domestically-made bivalent HPV vaccine to land, Wantai Bio's “bivalent HPV vaccine” will achieve revenue of 690 million yuan in 2020, accounting for 97.

In September 2020, Wantai Biotech's 9-valent HPV vaccine officially entered clinical phase III.

It can be said that the nucleic acid testing business and the bivalent HPV vaccine have truly brought Wantai Biotech to the pinnacle.

Not surprisingly, in the next three years, the competition between Bowei and Wantai Bio for the "9-valent HPV vaccine" will become more intense, and the unlisted Bowei will also compete for the "9-valent HPV vaccine" before it goes on the market.